PT  - JOURNAL ARTICLE
AU  - Sundaresan, Vaanathi
AU  - Arthofer, Christoph
AU  - Zamboni, Giovanna
AU  - Murchison, Andrew G.
AU  - Dineen, Robert A.
AU  - Rothwell, Peter M.
AU  - Auer, Dorothee P.
AU  - Wang, Chaoyue
AU  - Miller, Karla L.
AU  - Tendler, Benjamin C.
AU  - Alfaro-Almagro, Fidel
AU  - Sotiropoulos, Stamatios N.
AU  - Sprigg, Nikola
AU  - Griffanti, Ludovica
AU  - Jenkinson, Mark
TI  - Automated Detection of Cerebral Microbleeds on MR images using Knowledge Distillation Framework
AID  - 10.1101/2021.11.15.21266376
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.15.21266376
4099  - http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266376.short
4100  - http://medrxiv.org/content/early/2021/11/16/2021.11.15.21266376.full
AB  - Cerebral microbleeds (CMBs) are associated with white matter damage, various neu-rodegenerative and cerebrovascular diseases. CMBs occur as small, circular hypointense lesions on T2*-weighted gradient recalled echo (GRE) and susceptibility weighted imaging (SWI) images, and hyperintense on quantitative susceptibility mapping (QSM) images due to their paramagnetic nature. Accurate detection of CMBs would help to determine the CMB lesion count and distribution, which would be further useful to understand the clinical impact of CMBs and to obtain quantitative imaging biomarkers. In this work, we propose a fully automated, deep learning-based, 2-step algorithm, using structural and anatomical properties of CMBs from any single input image modality (e.g. GRE / SWI / QSM) for their accurate detection. Our method consists of an initial candidate detection step, that detects CMBs with high sensitivity and a candidate discrimination step using a knowledge distillation framework to classify CMB and non-CMB instances, followed by a morphological clean-up step. We used 4 datasets consisting of different modalities specified above, acquired using various protocols and with a variety of pathological and demographic characteristics. On cross-validation within datasets, our method achieved a cluster-wise true positive rate (TPR) over 90% with an average of less than 2 false positives per subject. Our method is flexible in terms of the input modality and provides comparable cluster-wise TPR and a better cluster-wise precision compared to existing state-of-the-art methods. When evaluated across different datasets, our method showed good generalisability with a cluster-wise TPR greater than 80% with different modalities.Competing Interest StatementMark Jenkinson receives royalties from licensing of FSL to non-academic, commercial parties.Funding StatementThis research was funded in part by the Wellcome Trust [203139/Z/16/Z]. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This work was also supported by the Engineering and Physical Sciences Research Council (EPSRC), Medical Research Council (MRC) [grant number EP/L016052/1], NIHR Nottingham Biomedical Research Centre and Wellcome Centre for Integrative Neuroimaging, which has core funding from the Wellcome Trust [203139/Z/16/Z]. The computational aspects of this research were funded from National Institute for Health Research (NIHR) Oxford BRC with additional support from the Wellcome Trust Core Award Grant Number 203141/Z/16/Z. The Oxford Vascular Study is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Wellcome Trust, Wolfson Foundation, the British Heart Foundation and the European Unions Horizon 2020 programme (grant 666881, SVDs@target). The TICH-2 MRI sub-study was funded by a grant from British Heart Foundation (grant reference PG/14/96/31262) and the TICH-2 trial was funded by a grant from the NIHR Health Technology Assessment programme (project code 11_129_109). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. VS is supported by the Wellcome Centre for Integrative Neuroimaging [203139/Z/16/Z]. CA was supported by NIHR Nottingham Biomedical Research Centre and is now supported by Wellcome Trust Collaborative Award [215573/Z/19/Z]. GZ is supported by the Italian Ministry of Education (MIUR) and by a grant Dipartimenti di eccellenza 2018-2022, MIUR, Italy, to the Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia. PMR is in receipt of a NIHR Senior Investigator award. KM and BT are funded by a Senior Research Fellowship from the Wellcome Trust (202788/Z/16/Z). MJ is supported by the NIHR Oxford Biomedical Research Centre (BRC), and this research was funded by the Wellcome Trust (215573/Z/19/Z). LG is supported by the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:OXVASC was approved by the South Central - Oxford A Research Ethics Committee (Research Ethics Committee reference number: 05/Q1604/70). Human subjects: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) to obtain and disseminate data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this study. Written informed consent was obtained from all participants. The TICH-2 trial obtained ethical approval from East Midlands (Nottingham 2) NHS Research Ethics Committee (Reference: 12/EM/0369) and the amendment to allow the TICH2 MRI sub-study was approved in April 2015 (amendment number SA02/15).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data from the OXVASC Study will be considered by P.M.R. in line with data protection laws. The TICH-2 MRI sub-study data can be shared with bona fide researchers and research groups on written request to the sub-study PI Prof Rob Dineen (rob.dineen{at}nottingham.ac.uk). Proposals will be assessed by the PI (with advice from the TICH-2 trial Steering Committee if required) and a Data Transfer Agreement will established before any data are shared. The UK Biobank and Hong Kong (HK) datasets are available to researchers through an open applications via https://www.ukbiobank.ac.uk/register-apply/ and http://www.cse.cuhk.edu.hk/~qdou/cmb-3dcnn/cmb-3dcnn.html respectively